Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TRE 515

Next Previous
Drug Profile

TRE 515

Alternative Names: DI-87; TRE-515

Latest Information Update: 03 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California at Los Angeles
  • Developer Harvard University; Stanford University; Trethera; University of California at Los Angeles
  • Class Anti-inflammatories; Antineoplastics; Diamines; Eye disorder therapies; Morpholines; Pyrimidines; Small molecules; Thiazoles
  • Mechanism of Action Deoxycytidine Kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute disseminated encephalomyelitis; Optic neuritis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Multiple sclerosis; Optic neuritis; Systemic lupus erythematosus
  • Research Crohn's disease

Most Recent Events

  • 25 Sep 2023 Early research in Crohn's disease in USA (PO)
  • 25 Sep 2023 Trethera Corporation receives Small Business Technology Transfer (STTR) grant from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) division of the National Institute of Health (NIH) for TRE 515 development in Crohn's disease
  • 14 Aug 2023 Trethera Corporation receives STTR grant from National Institute for Allergy and Infectious Diseases (NIAID) in the pediatric neurologic disease acute disseminated encephalomyelitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top